Literature DB >> 4204416

Quantitation of C3PA (properdin factor B) and other complement components in diseases associated with a low C3 level.

L H Perrin, P H Lambert, U E Nydegger, P A Miescher.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4204416     DOI: 10.1016/0090-1229(73)90032-9

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


× No keyword cloud information.
  16 in total

1.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

2.  Drug-combination therapy of rheumatoid arthritis.

Authors:  P A Miescher; H Favre; R Lemoine; P Tamagnini
Journal:  Springer Semin Immunopathol       Date:  1998

3.  Complement levels in pneumococcal pneumonia.

Authors:  J D Coonrod; B Rylko-Bauer
Journal:  Infect Immun       Date:  1977-10       Impact factor: 3.441

4.  Drug combination therapy of systemic lupus erythematosus.

Authors:  P A Miescher; H Favre; R Lemoine; Y P Huang
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Serum C3 and C4 levels and complement-dependent antibody-mediated cytotoxic activity of islet cell surface antibody in type 1 (insulin-dependent) diabetic children.

Authors:  S Okada; K Sato; Y Miyai; Y Masaki; T Higuchi; Y Ogino; Z Ota
Journal:  Diabetologia       Date:  1987-11       Impact factor: 10.122

6.  Activation of the alternative complement pathway in systemic lupus erythematosus.

Authors:  M R Wilson; C M Arroyave; R M Nakamura; J H Vaughan; E M Tan
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

7.  Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-ethylene glycol tetraacetic acid.

Authors:  R M Des Prez; C S Bryan; J Hawiger; D G Colley
Journal:  Infect Immun       Date:  1975-06       Impact factor: 3.441

8.  Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.

Authors:  M T Aguado; L H Perrin; R Ramirez; P A Miescher; P H Lambert
Journal:  Clin Exp Immunol       Date:  1980-12       Impact factor: 4.330

9.  Complement system in pneumococcal infections.

Authors:  W P Reed; M S Davidson; R C Williams
Journal:  Infect Immun       Date:  1976-04       Impact factor: 3.441

10.  Decreased heat-labile opsonic activity and complement levels associated with evidence of C3 breakdown products in infected pleural effusions.

Authors:  P D Lew; R Zubler; P Vaudaux; J J Farquet; F A Waldvogel; P H Lambert
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.